Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MECOM_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MECOM_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MECOM_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MECOM_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MECOM_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MECOM_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MECOM_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MECOM_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MECOM_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MECOM_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005140331 | Lung | MIAC | stress-activated MAPK cascade | 25/967 | 239/18723 | 6.50e-04 | 1.56e-02 | 25 |
GO:001657131 | Lung | MIAC | histone methylation | 17/967 | 141/18723 | 9.77e-04 | 2.04e-02 | 17 |
GO:003287322 | Lung | MIAC | negative regulation of stress-activated MAPK cascade | 9/967 | 51/18723 | 1.08e-03 | 2.15e-02 | 9 |
GO:007030322 | Lung | MIAC | negative regulation of stress-activated protein kinase signaling cascade | 9/967 | 51/18723 | 1.08e-03 | 2.15e-02 | 9 |
GO:000647931 | Lung | MIAC | protein methylation | 20/967 | 181/18723 | 1.11e-03 | 2.19e-02 | 20 |
GO:000821331 | Lung | MIAC | protein alkylation | 20/967 | 181/18723 | 1.11e-03 | 2.19e-02 | 20 |
GO:001820511 | Lung | MIAC | peptidyl-lysine modification | 34/967 | 376/18723 | 1.12e-03 | 2.19e-02 | 34 |
GO:003287223 | Lung | MIAC | regulation of stress-activated MAPK cascade | 20/967 | 192/18723 | 2.27e-03 | 3.45e-02 | 20 |
GO:000725421 | Lung | MIAC | JNK cascade | 18/967 | 167/18723 | 2.53e-03 | 3.62e-02 | 18 |
GO:007030231 | Lung | MIAC | regulation of stress-activated protein kinase signaling cascade | 20/967 | 195/18723 | 2.72e-03 | 3.75e-02 | 20 |
GO:004632821 | Lung | MIAC | regulation of JNK cascade | 15/967 | 133/18723 | 3.64e-03 | 4.60e-02 | 15 |
GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
GO:003109816 | Oral cavity | OSCC | stress-activated protein kinase signaling cascade | 141/7305 | 247/18723 | 5.74e-09 | 1.25e-07 | 141 |
GO:005140316 | Oral cavity | OSCC | stress-activated MAPK cascade | 134/7305 | 239/18723 | 6.02e-08 | 1.09e-06 | 134 |
GO:004340917 | Oral cavity | OSCC | negative regulation of MAPK cascade | 105/7305 | 180/18723 | 1.10e-07 | 1.87e-06 | 105 |
GO:007030210 | Oral cavity | OSCC | regulation of stress-activated protein kinase signaling cascade | 111/7305 | 195/18723 | 2.82e-07 | 4.34e-06 | 111 |
GO:003287210 | Oral cavity | OSCC | regulation of stress-activated MAPK cascade | 108/7305 | 192/18723 | 8.97e-07 | 1.22e-05 | 108 |
GO:003287310 | Oral cavity | OSCC | negative regulation of stress-activated MAPK cascade | 34/7305 | 51/18723 | 5.83e-05 | 4.80e-04 | 34 |
GO:007030310 | Oral cavity | OSCC | negative regulation of stress-activated protein kinase signaling cascade | 34/7305 | 51/18723 | 5.83e-05 | 4.80e-04 | 34 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MECOM | SNV | Missense_Mutation | novel | c.64N>T | p.His22Tyr | p.H22Y | | protein_coding | tolerated_low_confidence(0.65) | unknown(0) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
MECOM | SNV | Missense_Mutation | novel | c.1054C>T | p.His352Tyr | p.H352Y | Q03112 | protein_coding | tolerated(0.08) | probably_damaging(0.994) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
MECOM | SNV | Missense_Mutation | rs762099223 | c.1694C>A | p.Ala565Asp | p.A565D | Q03112 | protein_coding | deleterious(0.02) | benign(0.229) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
MECOM | SNV | Missense_Mutation | novel | c.1511N>C | p.Gln504Pro | p.Q504P | Q03112 | protein_coding | tolerated(0.46) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MECOM | SNV | Missense_Mutation | rs748747672 | c.710N>T | p.Ser237Leu | p.S237L | Q03112 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MECOM | SNV | Missense_Mutation | novel | c.1412N>T | p.Glu471Val | p.E471V | Q03112 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
MECOM | SNV | Missense_Mutation | | c.784N>C | p.Tyr262His | p.Y262H | Q03112 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
MECOM | SNV | Missense_Mutation | | c.295N>A | p.Pro99Thr | p.P99T | | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MECOM | SNV | Missense_Mutation | rs149892422 | c.256N>T | p.Arg86Cys | p.R86C | Q03112 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
MECOM | SNV | Missense_Mutation | | c.568N>A | p.Asp190Asn | p.D190N | Q03112 | protein_coding | tolerated(0.06) | possibly_damaging(0.787) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |